SG11201900427PA - Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding - Google Patents

Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding

Info

Publication number
SG11201900427PA
SG11201900427PA SG11201900427PA SG11201900427PA SG11201900427PA SG 11201900427P A SG11201900427P A SG 11201900427PA SG 11201900427P A SG11201900427P A SG 11201900427PA SG 11201900427P A SG11201900427P A SG 11201900427PA SG 11201900427P A SG11201900427P A SG 11201900427PA
Authority
SG
Singapore
Prior art keywords
international
baltimore
rule
fusion proteins
suite
Prior art date
Application number
SG11201900427PA
Inventor
David S Block
Henrik Olsen
Original Assignee
Gliknik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliknik Inc filed Critical Gliknik Inc
Publication of SG11201900427PA publication Critical patent/SG11201900427PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01111111111111111111111111111 111E1111 0111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date .....0\"\" WO 2018/018047 A3 25 January 2018 (25.01.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: A61K 39/395 (2006.01) CO7K 14/47 A61K 45/06 (2006.01) International Application Number: International Filing Date: 24 July 2017 (24.07.2017) Publication Language: Priority Data: 62/365,921 22 July 2016 (22.07.2016) 62/365,919 22 July 2016 (22.07.2016) Applicant: GLIKNIK INC. [US/US]; Street, Suite 501A, Baltimore, Maryland 21201 (US). Inventors: BLOCK, David S.; c/o Baltimore Street, Suite 501A, Baltimore, (US). OLSEN, Henrik; c/o Gliknik Inc., PCT/US2017/043538 (74) (2006.01) (81) English English US US 801 W. Baltimore (84) Gliknik Inc., 801 W. Agent: PHELAN, Jordan D. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Maryland 21201 801 W. Baltimore 21201 (US). Street, Suite 501A, Baltimore, Maryland = = = the (54) present 0 multimeric Title: FUSION PROTEINS OF HUMAN FC COMPOSITIONS WITH ENHANCED FC RECEPTOR GL2045 Fc7R1 MUNOGLOBULIN PROTEIN FRAGMENTS FIG. Fc7R118 .,........— ,..._ 1 TO CREATE ORDERLY MULTIMERIZED BINDING FeyRITIA F cyR.IIA .... - IM- thereby ordered useful — = = = = = = = = = = _ = ... ,. M IN 7r CZ GC 11 CZ --- -- GO (57) \" in : The present invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly fractions, termed stradomers. The invention involves fusion proteins that bind to FcyRs and complement and that are treatment and prevention of disease. [Continued on next page] WO 2018/018047 A3 MUNRO DOI 01011MERIONIMOHMONHOHMIN TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018)
SG11201900427PA 2016-07-22 2017-07-24 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding SG11201900427PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365919P 2016-07-22 2016-07-22
US201662365921P 2016-07-22 2016-07-22
PCT/US2017/043538 WO2018018047A2 (en) 2016-07-22 2017-07-24 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding

Publications (1)

Publication Number Publication Date
SG11201900427PA true SG11201900427PA (en) 2019-02-27

Family

ID=60992683

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900427PA SG11201900427PA (en) 2016-07-22 2017-07-24 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding

Country Status (12)

Country Link
US (1) US20190389941A1 (en)
EP (1) EP3487534A4 (en)
JP (1) JP2019530642A (en)
KR (1) KR20190032392A (en)
CN (1) CN109641048A (en)
AU (1) AU2017300794A1 (en)
BR (1) BR112019001156A2 (en)
CA (1) CA3029744A1 (en)
IL (1) IL264257A (en)
MX (1) MX2019000887A (en)
SG (1) SG11201900427PA (en)
WO (1) WO2018018047A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
CN110177802A (en) 2016-12-09 2019-08-27 格利克尼克股份有限公司 The manufacture of multimerization stradomer GL-2045 optimizes
BR112019009495A2 (en) 2016-12-09 2019-08-06 Gliknik Inc methods of treating inflammatory disorders with multivalent fc compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109362T3 (en) 1991-06-21 1998-01-16 Univ Cincinnati ADMINISTRABLE PROTEINS ORALLY AND METHOD TO MAKE THEM.
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
CN107011445B (en) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 Immunoglobulin constant region Fc receptor binding agents
US8815237B2 (en) * 2007-12-05 2014-08-26 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
MX2011007833A (en) * 2009-01-23 2011-10-06 Biogen Idec Inc Stabilized fc polypeptides with reduced effector function and methods of use.
DK2598533T3 (en) * 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
EP2862875B1 (en) * 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
CN104736174B (en) * 2012-07-06 2019-06-14 根马布私人有限公司 Protein dimer with triple mutant
CN104870055A (en) 2012-10-17 2015-08-26 利物浦热带医学院 Immunomodulatory proteins
WO2015132365A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
EP3131926A1 (en) 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
SG11201607070VA (en) 2014-05-02 2016-11-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
GB201412821D0 (en) 2014-07-18 2014-09-03 Liverpool School Tropical Medicine Polymeric proteins and uses thereof
PT3221346T (en) * 2014-11-21 2020-10-23 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
US20180044416A1 (en) 2015-03-05 2018-02-15 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
KR20240042137A (en) 2015-07-24 2024-04-01 글리크닉 인코포레이티드 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
GB201515745D0 (en) 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins

Also Published As

Publication number Publication date
WO2018018047A2 (en) 2018-01-25
US20190389941A1 (en) 2019-12-26
WO2018018047A3 (en) 2018-03-01
EP3487534A4 (en) 2020-03-25
IL264257A (en) 2019-02-28
JP2019530642A (en) 2019-10-24
CN109641048A (en) 2019-04-16
MX2019000887A (en) 2019-09-04
BR112019001156A2 (en) 2019-04-30
KR20190032392A (en) 2019-03-27
AU2017300794A1 (en) 2019-01-24
EP3487534A2 (en) 2019-05-29
CA3029744A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201804857WA (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201804969PA (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods